Year |
Citation |
Score |
2020 |
Allon R, Aronov M, Belkin M, Maor E, Shechter M, Fabian ID. Retinal Microvascular Signs as Screening and Prognostic Factors for Cardiac Disease: A Systematic Review of Current Evidence. The American Journal of Medicine. PMID 32861624 DOI: 10.1016/J.Amjmed.2020.07.013 |
0.305 |
|
2020 |
Sara JDS, Maor E, Borlaug B, Lewis BR, Orbelo D, Lerman LO, Lerman A. Non-invasive vocal biomarker is associated with pulmonary hypertension. Plos One. 15: e0231441. PMID 32298301 DOI: 10.1371/Journal.Pone.0231441 |
0.317 |
|
2020 |
Maor E, Perry D, Mevorach D, Taiblum N, Luz Y, Mazin I, Lerman A, Koren G, Shalev V. Vocal Biomarker Is Associated With Hospitalization and Mortality Among Heart Failure Patients. Journal of the American Heart Association. 9: e013359. PMID 32233754 DOI: 10.1161/Jaha.119.013359 |
0.316 |
|
2020 |
Berkovitch A, Barbash IM, Finkelstein A, Assali AR, Danenberg H, Fefer P, Maor E, Zhitomirsky S, Orvin K, Zekry SB, Steinvil A, Barsheshet A, Halkin A, Guetta V, Kornowski R, et al. Validation of cardiac damage classification and addition of albumin in a large cohort of patients undergoing transcatheter aortic valve replacement. International Journal of Cardiology. PMID 32008849 DOI: 10.1016/J.Ijcard.2020.01.031 |
0.329 |
|
2020 |
Peled Y, Eilon R, Maor E, Einhorn M, Lavee J, Klempfner R. High Serum Phosphate is Associated with Increased Cardiac Allograft Vasculopathy and Adverse Cardiac Events Following Heart Transplantation The Journal of Heart and Lung Transplantation. 39: S245. DOI: 10.1016/J.Healun.2020.01.927 |
0.311 |
|
2019 |
Maor E, Sugrue A, Witt C, Vaidya VR, DeSimone CV, Asirvatham SJ, Kapa S. Pulsed electric fields for cardiac ablation and beyond: A state of the art review. Heart Rhythm. PMID 30641148 DOI: 10.1016/J.Hrthm.2019.01.012 |
0.317 |
|
2019 |
Berkovitch A, Barbash IM, Finkelstein A, Assali AR, Denenberg H, Fefer P, Maor E, Zhitomirsky S, Orvin K, Steinvil A, Barsheset A, Halkin A, Guetta V, Kornowski R, Segev A. P3857Validation of the cardiac damage classification and additional effects of albumin levels in a large cohort of patients undergoing transcatheter aortic valve replacement European Heart Journal. 40. DOI: 10.1093/Eurheartj/Ehz745.0695 |
0.316 |
|
2019 |
Peled Y, Ram E, Har-Zahav Y, Shlomo N, Kassif Y, Kogan A, Maor E, Freimark D, Klempfner R, Lavee J. Metformin Therapy is Associated with Reduced Risk of Vasculopathy and Cardiovascular Mortality after Heart Transplantation Journal of Heart and Lung Transplantation. 38. DOI: 10.1016/J.Healun.2019.01.698 |
0.313 |
|
2018 |
Finkelstein A, Rozenbaum Z, Halkin A, Banai S, Bazan S, Barbash I, Segev A, Fefer P, Maor E, Danenberg H, Planner D, Orvin K, Assa HV, Assali A, Kornowski R, et al. Outcomes of Transcatheter Aortic Valve Implantation in Patients With Low Versus Intermediate to High Surgical Risk. The American Journal of Cardiology. PMID 30528420 DOI: 10.1016/J.Amjcard.2018.11.010 |
0.32 |
|
2018 |
Kuperstein R, Klempfner R, Ofek E, Maor E, Freimark D, Sternik L, Goldenberg I, Raanani E, Arad M. De novo mitral regurgitation as a cause of heart failure exacerbation in patients with hypertrophic cardiomyopathy. International Journal of Cardiology. 252: 122-127. PMID 29174016 DOI: 10.1016/J.Ijcard.2017.11.060 |
0.303 |
|
2017 |
Fefer P, Kohen S, Bogdan A, Guetta V, Asher E, Maor E, Elian D, Regev E, Fink N, Segev A, Barbash IM. RAPID VENTRICULAR PACING DURING TAVR IS ASSOCIATED WITH POOR SHORT- AND LONG-TERM OUTCOME Journal of the American College of Cardiology. 69: 1343. DOI: 10.1016/S0735-1097(17)34732-0 |
0.325 |
|
2014 |
Ramaty E, Maor E, Peltz-Sinvani N, Brom A, Grinfeld A, Kivity S, Segev S, Sidi Y, Kessler T, Sela BA, Segal G. Low ALT blood levels predict long-term all-cause mortality among adults. A historical prospective cohort study European Journal of Internal Medicine. 25: 919-921. PMID 25468741 DOI: 10.1016/J.Ejim.2014.10.019 |
0.311 |
|
2014 |
Maor E, Beigel R, Grupper A, Kuperstein R, Hai I, Medvedofsky D, Perelstein O, Mazin I, Ziv A, Goldenberg I, Feinberg MS, Ben Zekry S. Relation between stroke volume index to risk of death in patients with low-gradient severe aortic stenosis and preserved left ventricular function. The American Journal of Cardiology. 114: 449-55. PMID 24948491 DOI: 10.1016/J.Amjcard.2014.05.014 |
0.328 |
|
2014 |
Grupper A, Beigel R, Maor E, Kuperstein R, Hai I, Perelshtein O, Goldenberg I, Feinberg M, Ben Zekry S. Survival after intervention in patients with low gradient severe aortic stenosis and preserved left ventricular function. The Journal of Thoracic and Cardiovascular Surgery. 148: 2823-7. PMID 24787695 DOI: 10.1016/J.Jtcvs.2014.03.039 |
0.301 |
|
2013 |
Koifman E, Kopel E, Medvedovsky D, Maor E, Hamdan A, Goldenberg I, Klempfner R. Age-dependent effect of left ventricular ejection fraction on long-term mortality in patients with heart failure (from the Heart Failure Survey in ISrael). The American Journal of Cardiology. 112: 1901-6. PMID 24063837 DOI: 10.1016/J.Amjcard.2013.08.015 |
0.327 |
|
2013 |
Maor E, Beigel R, Grupper A, Kuperstein R, Perelstein O, Mazin I, Goldenberg I, Feinberg M, Ben Zekry S. Low stroke volume index is an independent predictor of mortality among patients with low gradient severe aortic stenosis and preserved left ventricle function European Heart Journal. 34: P4737-P4737. DOI: 10.1093/Eurheartj/Eht310.P4737 |
0.359 |
|
2013 |
Koifman E, Kopel E, Medvedovsky D, Maor E, Hamdan A, Goldenberg I, Klempfner R. Differential effect of left ventricular ejection fraction on long term mortality in patients hospitalized with acute heart failure. Data from the HFSIS 2003 registry European Heart Journal. 34: 1494. DOI: 10.1093/Eurheartj/Eht308.P1494 |
0.328 |
|
2013 |
Koifman E, Kopel E, Rozen G, Maor E, Fefer P, Matezky S, Hamdan A, Goldenberg I, Klempfner R. Predictors of mineralocorticoid receptor antagonist utilization in patients with left ventricular dysfunction following acute myocardial infarction: real world data from the acute coronary syndrome IS European Heart Journal. 34: 1336. DOI: 10.1093/Eurheartj/Eht308.P1336 |
0.315 |
|
2011 |
Phillips M, Maor E, Rubinsky B. Principles of tissue engineering with nonthermal irreversible electroporation Journal of Heat Transfer. 133. DOI: 10.1115/1.4002301 |
0.521 |
|
2010 |
Maor E, Ivorra A, Mitchell JJ, Rubinsky B. Vascular smooth muscle cells ablation with endovascular nonthermal irreversible electroporation. Journal of Vascular and Interventional Radiology : Jvir. 21: 1708-15. PMID 20933436 DOI: 10.1016/J.Jvir.2010.06.024 |
0.473 |
|
2010 |
Phillips M, Maor E, Rubinsky B. Nonthermal irreversible electroporation for tissue decellularization. Journal of Biomechanical Engineering. 132: 091003. PMID 20815637 DOI: 10.1115/1.4001882 |
0.505 |
|
2010 |
Maor E, Rubinsky B. Endovascular nonthermal irreversible electroporation: a finite element analysis. Journal of Biomechanical Engineering. 132: 031008. PMID 20459196 DOI: 10.1115/1.4001035 |
0.505 |
|
2009 |
Granot Y, Ivorra A, Maor E, Rubinsky B. In vivo imaging of irreversible electroporation by means of electrical impedance tomography. Physics in Medicine and Biology. 54: 4927-43. PMID 19641242 DOI: 10.1088/0031-9155/54/16/006 |
0.678 |
|
2009 |
Maor E, Ivorra A, Rubinsky B. Non thermal irreversible electroporation: novel technology for vascular smooth muscle cells ablation. Plos One. 4: e4757. PMID 19270746 DOI: 10.1371/Journal.Pone.0004757 |
0.498 |
|
2008 |
Maor E, Ivorra A, Rubinsky B. Intravascular irreversible electroporation: theoretical and experimental feasibility study. Conference Proceedings : ... Annual International Conference of the Ieee Engineering in Medicine and Biology Society. Ieee Engineering in Medicine and Biology Society. Annual Conference. 2008: 2051-4. PMID 19163098 DOI: 10.1109/IEMBS.2008.4649595 |
0.444 |
|
2008 |
Maor E, Ivorra A, Leor J, Rubinsky B. Irreversible electroporation attenuates neointimal formation after angioplasty. Ieee Transactions On Bio-Medical Engineering. 55: 2268-74. PMID 18713696 DOI: 10.1109/Tbme.2008.923909 |
0.505 |
|
2007 |
Maor E, Ivorra A, Leor J, Rubinsky B. The effect of irreversible electroporation on blood vessels. Technology in Cancer Research & Treatment. 6: 307-12. PMID 17668938 DOI: 10.1177/153303460700600407 |
0.512 |
|
Show low-probability matches. |